The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background: Among the most harmful of all genetic abnormalities that appear in colorectal cancer (CRC) development are mutations of KRAS and its downstream effector BRAF as they result in abnormal extracellular signal-related kinase (ERK) signaling. In a previous report, we had shown that expression of a constitutive active mutant of MEK1 (caMEK) in normal rat intestinal epithelial cells (IECs) induced morphological transformation associated with epithelial to mesenchymal transition, growth in soft agar, invasion and metastases in nude mice. Results from microarrays comparing control to caMEK-expressing IECs identified the gene encoding for serpinE2, a serine protease inhibitor, as a potential target of activated MEK1. Results: 1- RT-PCR and western blot analyses confirmed the strong up-regulation of serpinE2 expression and secretion by IECs expressing oncogenic MEK, Ras or BRAF. 2- Interestingly, serpinE2 mRNA and protein were also markedly enhanced in human CRC cells exhibiting mutation in KRAS and BRAF. 3- RNAi directed against serpinE2 in caMEK-transformed rat IECs or in human CRC cell lines HCT116 and LoVo markedly decreased foci formation, anchorage-independent growth in soft agarose, cell migration and tumor formation in nude mice. 4- Treatment of CRC cell lines with U0126 markedly reduced serpinE2 mRNA levels, indicating that expression of serpinE2 is likely dependent of ERK activity. 5- Finally, Q-PCR analyses demonstrated that mRNA levels of serpinE2 were markedly increased in human adenomas in comparison to healthy adjacent tissues and in colorectal tumors, regardless of tumor stage and grade. Conclusions: Our data indicate that serpinE2 is up-regulated by oncogenic activation of Ras, BRAF and MEK1 and contributes to pro-neoplastic actions of ERK signaling in intestinal epithelial cells. Hence, serpinE2 may be a potential therapeutic target for colorectal cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788 · cited 1×
“Therefore, much emphasis has been placed on treatment strategies that target this protein kinase cascade [10].”
BackgroundThe MAPK signalling pathways and colorectal cancer
Fang, J. Y., & Richardson, B. C. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70168-6 · Cited by 1,185 · cited 1×
“Together, these observations strengthen the notion that ERK1/2 MAP kinase signaling may play a critical role in CRC progression [16].”
Background
Cited by
Wiśniewski, J. R., Ostasiewicz, P., & Mann, M. (2011) · Journal of Proteome Research · doi:10.1021/pr200019m · Cited by 290
Zhuang, A., Zhuang, A., Chen, Y., Qin, Z., Zhu, D., Ren, L., Wei, Y., Zhou, P., Yue, X., He, F., et al. (2023) · eLife · doi:10.7554/elife.82959 · Cited by 14
Gomez, A. R., Byun, H. R., Wu, S., Muhammad, A. K. M. G., Ikbariyeh, J., Chen, J., Muro, A., Li, L., Bernstein, K. E., Ainsworth, R., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00879-1 · Cited by 13
Metadata
- Authors
- Bergeron, S., Lemieux, E., Durand, V., Cagnol, S., Carrier, J. C., Lussier, J. G., Boucher, M.-J., & Rivard, N.
- Venue
- Molecular Cancer
- Published
- 2010-10-13
- Volume
- 9
- Issue
- 1
- Pages
- 271-271
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W2110962636
- Cited by
- 81
- References
- 2
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis. https://app.cochat.ai/papers/10.1186/1476-4598-9-271
- The paper
- Bergeron, S., Lemieux, E., Durand, V., Cagnol, S., Carrier, J. C., Lussier, J. G., Boucher, M.-J., & Rivard, N. (2010). The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis. Molecular Cancer. https://doi.org/10.1186/1476-4598-9-271
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.